News

The project, a collaboration with researchers from the University of Maryland, holds promise for advancing new and more tolerable drug treatments for common chronic blinding eye diseases, including glaucoma and macular degeneration.

According to the company, AG-73305 was found to be safe and tolerable with no severe adverse effects after a single intravitreal injection of 0.5 mg and 1 mg in patients diagnosed with diabetic macular edema.

According to the company, topical administration is capable of delivering metformin to choroid, RPE, and retina.

SLT shows promise as treatment for millions of Africans with glaucoma.

Louis R. Pasquale, MD, FARVO, will be presented the award by previous winner Robert N. Weinreb, MD.

According to the company, the study has now reached its goal of 300 patients enrolled to evaluate ILUVIEN as a first line, baseline therapy for DME.

The investigative team wanted to provide physicians with reference guidelines to aid in the prevention and control of myopia.

Macular hole closure results from this novel treatment.

Instrumentation recreates properties of the myopic eye to test lenses that prevent visual decline.

According to the company, study results show sustained reductions in both IOP and glaucoma medication use in mild-moderate primary open angle glaucoma patients treated with a procedure enabled with the OMNI Surgical System technology.

In a recent update, the CDC has noted an additional death, bringing the death toll up to 4, with numerous counts of vision loss across the US.

Data demonstrate a reduction in the loss of retinal pigmented epithelial and photoreceptor cells.

The two companies have announced an exclusive agreement for Polifarma to commercialize AVT06, the proposed biosimilar to Eylea, in Turkey.

According to the company, the Phase 1 trial is a multicenter, open-label, dose-escalation safety clinical trial. Up to 24 subjects will receive a single periocular injection and will undergo monthly evaluation for up to 6 months to assess safety, tolerability, and efficacy measured by best corrected visual acuity.

According to the company, the DIAMOND trial in diabetic macular edema with topical OCS-01 met its stage 1 objective of validating the loading and maintenance dosing regimen designed to optimize OCS-01 efficacy potential with robust statistical significance.

Study: AO retinal imaging has the potential to become a sensitive marker for disease.

The company noted tanfanercept did not demonstrate statistical significance in either of the primary outcome measures of improvement in central corneal staining score or in improvement in Eye Dryness Score assessed at week 8 in subjects with dry eye disease, compared to vehicle. However, tanfanercept did demonstrate a highly statistically significant improvement on one of the secondary outcome measures, Schirmer testing of tear volume.

Ophthalmology Times reached out to members of its editorial advisory board along with ophthalmologists who specialize in dry eye for their comments on what this approval means for their patients with dry eye.

The number of cases continues to rise throughout the world

According to the companies, MIEBO is the first and only prescription eye drop approved for dry eye disease that directly targets tear evaporation, based on consistent results from a pair of pivotal Phase 3 trials.

During the 26th annual meeting of the American Society of Gene & Cell Therapy, taking place through Saturday in Los Angeles, California, the company is delivering several presentations highlighting its AAV capsids and gene constructs.

The lawsuit states the $27.8 billion acquisition would allow Amgen to strengthen their drug portfolio and stifle drug competition in a bid to monopolize two fast-growing medications.

The American Academy of Ophthalmology Truhlsen-Marmor Museum of the Eye, a free public museum dedicated to the science of sight, will present Decoding the Eye.: Signs and Symbols.

The company noted YUTIQ is used for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and is the same as Alimera’s ILUVIEN.

Clinical judgment is not always sufficient to determine whether a patient has an inherited corneal disorder.

In a presentation at the American Society of Cataract and Refractive Surgery meeting in San Diego, Kenneth A. Beckman, MD, FACS, discussed the current status of corneal crosslinking with some emerging treatments, including epi-on crosslinking.

Earlier this year, a federal civil jury concluded that the defendants violated the False Claims Act and the Anti-Kickback Statute by paying kickbacks to ophthalmic surgeons to induce their use of the defendants’ products in cataract surgeries reimbursed by Medicare.

Diana V. Do, MD, presented details of the PHOTON study at the Association for Research in Vision and Ophthalmology annual meeting, held recently in New Orleans, highlighting the safety and efficacy of 8 milligrams of aflibercept.

Groundbreaking treatment for patients with bullous keratopathy approved in Japan.